Key result
Papillary endothelial hyperplasia presents as small circumscribed masses unlike larger ill-defined invasive angiosarcomas.
Population
8 patients with lesions diagnosed on breast core needle biopsy. Mean age 62 for PEH and 33 for primary…
Design
Case_series
Follow-up
2-11 years for PEH, 3-6 years for angiosarcoma
Authors
Loading...
Biopsy features may aid PEH-angiosarcoma distinction; case-level data leave diagnostic criteria open for validation.
Observational (n=8)
Clinical, imaging, and histologic correlation is essential to distinguish benign papillary endothelial hyperplasia from malignant angiosarcoma on breast core needle biopsy.
Guilbert et al. (2018) conducted an observational in Papillary endothelial hyperplasia and angiosarcoma of the breast (n=8). Papillary endothelial hyperplasia vs. Angiosarcoma was evaluated on Clinical, radiologic, and pathologic features. Papillary endothelial hyperplasia presented as small, circumscribed masses (mean 0.9 cm) vs angiosarcoma which formed larger, ill-defined masses (mean 2.8 cm) invading fibrous stroma.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: